FLXN - Flexion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Flexion Therapeutics, Inc.

10 Mall Road
Suite 301
Burlington, MA 01803
United States

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees272

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael D. ClaymanCo-Founder, Pres, CEO & Director883.23kN/A1952
Dr. Neil BodickCo-Founder & Chief Scientific Officer602.06k971.96k1947
Mr. David A. ArkowitzChief Financial Officer414.99kN/A1961
Mr. Mark S. LevineGen. Counsel & Sec.544.39kN/A1973
Dr. Scott D. KelleyChief Medical Officer540.56kN/A1959
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Corporate Governance

Flexion Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.